6533b7d3fe1ef96bd126143a
RESEARCH PRODUCT
Bovine lactoferrin prevents invasive fungal infections in very low birth weight infants: a randomized controlled trial.
P ManzoniI StolfiH MessnerS CattaniN La ForgiaMg RomeoL BollaniM RinaldiE GalloM QuerciaM MauleL DecembrinoR MagaldiF MoscaE VagnarelliL MemoPm BettaM StronatiD FarinaA BorghesiC TziallaG AgriestiR ArisioC FrancoP Del SordoGuardione RE BoanoA CatarinellaC RomanoS RizzolloL BarberisC MonettiU SalaC CarbonaraE MastrettaC PrioloP GallettoF CampagnoliM VivaldaM CuozzoG BonfanteG GomiratoC GiovannozziD CipollaGiovanni CorselloF NataleG CoronaF TumminelliG VetranoE TridapalliG FaldellaSv PiconePm PaolilloE CaliendoL PugniG GarganoC MagnaniL RenzulloL BordignonOs SaiaE Della CasaF FerrariR. Pedicinosubject
fungal sepsisDiseasesInfant Premature DiseasesPediatricsGastroenterologylactoferrin; VLBW neonates; Candida; fungal sepsis; prophylaxisGroup BSettore MED/38 - Pediatria Generale E SpecialisticaAnti-Infective AgentsInfant Very Low Birth WeightCandidabiologyLactoferrinBovine lactoferrin fungal infections very low birth weight newbornsPerinatology and Child Healthlactoferrinprophylaxismedicine.symptomInfant Prematuremedicine.medical_specialtyFungal sepsisPlaceboSepsisLactobacillus rhamnosusIntolerancesInternal medicinemedicineAnimalsHumansfungal sepsiAdverse effectPrematureProphylaxisbusiness.industryVery Low Birth WeightProbioticsInfant NewbornInfantNewbornbiology.organism_classificationmedicine.diseaseLactoferrinLow birth weightMycosesVLBW neonatesPediatrics Perinatology and Child HealthImmunologyCandida; Fungal sepsis; Lactoferrin; Prophylaxis; VLBW neonates; Animals; Anti-Infective Agents; Cattle; Humans; Infant Newborn; Infant Premature; Infant Premature Diseases; Lactoferrin; Mycoses; Probiotics; Infant Very Low Birth Weight; Pediatrics Perinatology and Child Healthbiology.proteinCattlebusinessdescription
Background: Lactoferrin is a mammalian milk glycoprotein involved in innate immunity. Recent data show that bovine lactoferrin (bLF) prevents late-onset sepsis in preterm very low birth weight (VLBW) neonates. Methods: This is a secondary analysis of data from a multicenter randomized controlled trial where preterm VLBW neonates randomly received bLF (100 mg/day; group A1), bLF + Lactobacillus rhamnosus GG (106 colony-forming units per day; group A2), or placebo (group B) for 6 weeks. Here we analyze the incidence rates of fungal colonization, invasive fungal infection (IFI), and rate of progression from colonization to infection in all groups. Results: This study included 472 neonates whose clinical, nutritional, and demographical characteristics were similar. Overall, the incidence of fungal colonization was comparable (17.6%, 16.6%, and 18.5% in A1, A2, and B, respectively; P = .89 [A1] and .77 [A2]). In contrast, IFIs were significantly decreased in A1 and A2 (0.7% and 2.0%, respectively) compared with B (7.7%; P = .002 [A1] and .02 [A2]), and this was significantly true both in <1000 g (0.9% [A1] and 5.6% [A2], vs 15.0%) and in 1001 to 1500 g infants (0% and 0% vs 3.7%). The progression rate colonization-infection was significantly lower in the bLF groups: 3.7% (A1) and 12% (A2), vs 41.9%; P < .001 (A1) and P = .02 (A2). No IFI-attributable deaths occurred in the treatment groups, versus 2 in placebo. No adverse effects or intolerances occurred. Conclusions: Prophylactic oral administration of bLF reduces the incidence of IFI in preterm VLBW neonates. No effect is seen on colonization. The protective effect on IFI is likely due to limitation of ability of fungal colonies to progress toward invasion and systemic disease in colonized infants.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2011-12-21 |